New combo therapy shows promise in CML battle
NCT ID NCT02201459
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This study tested whether adding a drug called pegylated interferon to the standard treatment nilotinib helps people with newly diagnosed chronic myeloid leukemia (CML) achieve a deeper molecular response. 200 adults under 65 took part. The goal was to see if the combination leads to better control of the disease at 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Franck NICOLINI
Lyon, 04 78 86 22 50, France
Conditions
Explore the condition pages connected to this study.